News & Analysis as of

Venture Capital Biotechnology

WilmerHale

Royalty Financings and Similar Revenue Monetizations Surge in Difficult Life Sciences Fundraising Environment

WilmerHale on

Many biopharmaceutical companies are facing challenges raising cash through traditional equity markets. While venture investment activity saw a slight increase in the first half of 2024 as compared to the equivalent period in...more

Gardner Law

Navigating the Biosecure Act: Implications for Biotechnology and Pharmaceutical Companies

Gardner Law on

The Biosecure Act, introduced in January 2024 (H.R. 7085), has garnered significant bipartisan support and is increasingly poised to become law, heightening its impact on the life sciences industry. The bill, now amended to...more

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

McDermott Will & Emery

Pharma and MedTech Services Investment Summit 2024

McDermott Will & Emery on

The inaugural Pharma and MedTech Services Investment Summit brought together C-suite executives, senior private equity professionals, investment bankers and other industry leaders for a deep dive into the investment...more

Wilson Sonsini Goodrich & Rosati

The Life Sciences Report – June 2024

This latest edition features articles on biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, life sciences venture financings for clients in 2023, and updated USPTO...more

McDermott Will & Emery

[Event] Pharma and MedTech Services Investment Summit 2024 - May 2nd, San Francisco, CA

McDermott Will & Emery on

YOUR SOURCE FOR SUCCESS IN PHARMA AND DEVICE SERVICES INVESTING - Join C-suite executives, senior private equity professionals, investment bankers and other industry leaders for a deep dive into the investment...more

Troutman Pepper

Ready for the Biotech Bounce Back in 2024?

Troutman Pepper on

Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2024

This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more

Fenwick & West LLP

Reflections on the J.P. Morgan Healthcare Conference: Key Themes for 2024

Fenwick & West LLP on

The Fenwick life sciences team recently returned from the 2024 JP Morgan Healthcare conference. As we reflect back on the week, there were several key themes and trends that we expect will continue to resonate and evolve over...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include: Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more

AEON Law

EU Study Shows Startups with IP 1000% More Likely to Be Funded

AEON Law on

The European Patent Office (EPO) and the European Union Intellectual Property Office (EUIPO) have released a 61-page study showing that EU startups that secure intellectual property (IP) rights protection are 10.2 times more...more

Mintz

Client Corner: Meet Biotech Executive John Edwards

Mintz on

Our Client Corner: Perspectives from Founders, Financiers, and Friends podcast series hosted by Mintz Member Joshua Fox explores the dynamics of starting and running a business, investing in a business, and helping to support...more

Foley & Lardner LLP

Strengthening the Flow of the Biotech Sector’s M&A Pipeline

Foley & Lardner LLP on

Originally published in Genetic Engineering News on October 10, 2023. Reprinted with permission. The biotechnology sector has long been characterized by its constant innovation, rapid technological progress, and unyielding...more

Foley & Lardner LLP

Navigating the AI Frontier: Legal and Operational Insights Into Generative AI

Foley & Lardner LLP on

In our ever-changing technological environment, artificial intelligence (AI) is beginning to exert its influence on numerous sectors, revolutionizing our approach to work. As businesses and organizations worldwide adopt...more

Mintz - Venture Capital & Emerging Companies...

Five Ways To Target Success As A Startup

Turning innovation into a successful business can be daunting. In a panel discussion at the 2023 BIO International Convention, Mintz’s Josh Fox, who is a Member in our Chambers-ranked Life Sciences practice, alongside...more

Allen Matkins

Life Sciences Real Estate Update - 7.18.23

Allen Matkins on

California was, by January 1, 2023, home to nearly 470,000 jobs that generated $413.7 billion in total business output in 2022, according to Biocom California’s 2023 Economic Impact Report. This represents a nearly 8 percent...more

Hogan Lovells

Strategic financial options for clinical stage life sciences companies in a troubled equity market

Hogan Lovells on

Early 2023 has seen new and unprecedented financial challenges for clinical stage life sciences companies. The financing rounds of 2021 and 2022 are starting to run off, while at the same time the equity markets are either...more

Allen Matkins

Life Sciences Real Estate Update -1.06.23 #1

Allen Matkins on

California’s lab and biotech industries provide 435,693 jobs that generate $376 billion in total economic output, according to a new report from Biocom California, an association representing life sciences companies and...more

Hogan Lovells

JPM2023 Trendspotting: portfolio valuation in the aftermath of the IRA

Hogan Lovells on

As the industry readies itself for the January 2023 pilgrimage to the J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry team has prepared...more

Allen Matkins

Life Sciences Real Estate Update - September 2022

Allen Matkins on

Average sale price for U.S. life sciences properties hits record high Bullet Commercial Observer – August 17 According to a recent Newmark report, the national average sale price for a life sciences lab space reached a record...more

Foley & Lardner LLP

Funding Oases for Biotechs: How Biotechnology Companies at All Stages Can Succeed Through Lean Times

Foley & Lardner LLP on

Recent reporting by the Financial Times shows that valuations and funding for biotech companies has fallen significantly, as “just nine biotech companies have listed in the U.S. this year, raising a total of $1bn … almost 60...more

Hogan Lovells

World Stem Cell Summit offers guidance on positioning your regenerative medicine start-up for success

Hogan Lovells on

Speaking at the World Stem Cell Summit hosted by the Regenerative Medicine Foundation, Hogan Lovells partners Andrew Strong and Barry Burgdorf provided best practices for launching a start-up biotech company in the cell,...more

Gould + Ratner LLP

Ten Talks - Focus on Women Entrepreneurs - Conversation with Catherine Kleinmuntz

Gould + Ratner LLP on

In this first episode of our new series of video conversations focused on highlighting and showcasing women entrepreneurs in venture capital and private equity, Corporate Associate Ammara Khan talks with Principal of...more

Rothwell, Figg, Ernst & Manbeck, P.C.

Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes

On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing, co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital...more

Rothwell, Figg, Ernst & Manbeck, P.C.

Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies

Capsida Biotherapeutics Inc.—a  Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital. Capsida secured a $50 million Series A commitment from Versant...more

50 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide